Last updated: February 16, 2026
Overview
NDC 70000-0455 is a pharmaceutical product marketed by Fresenius Kabi, primarily used in intravenous nutrition. Market dynamics, competitive landscape, manufacturing costs, and reimbursement trends influence its pricing and outlook.
Product Characteristics
- Drug Class: Parenteral nutrition (PN)
- Formulation: Multi-component amino acid, lipid, carbohydrate solutions
- Indications: Support nutritional needs in critically ill, postoperative, or malnourished patients
- Presentation: Varies but typically supplied as multi-dose vials or bags
Market Size and Trends
- The global parenteral nutrition market was valued at approximately $4.8 billion in 2022.
- Compound annual growth rate (CAGR): 4.1% (2023-2030).
- Major drivers: increasing prevalence of malnutrition, aging populations, surgical procedures, and critical care demand.
Competitive Landscape
- Key competitors include Hospira (now part of Pfizer), Baxter International, B. Braun, and Grifols.
- Market share distribution (2022):
| Company |
Market Share (%) |
| Fresenius Kabi |
40 |
| Baxter |
35 |
| B. Braun |
15 |
| Others |
10 |
- NDC 70000-0455's positioning depends on formulation, pricing, and distribution agreements.
Pricing Analysis
- Average wholesale price (AWP) for similar PN products:
| Manufacturer |
Estimated AWP per 100 mL |
Notes |
| Fresenius Kabi |
$15 |
Average for multi-component solutions |
| Baxter |
$17 |
Slight premium reflecting formulation complexity |
| B. Braun |
$14 |
Competitive positioning |
- Typical wholesale acquisition cost (WAC): 10-15% lower than AWP.
| Price Range (Per 100 mL) |
Approximate WAC |
Marketed Price Strategy |
| $13.50 - $15.00 |
$12.00 - $13.50 |
Market penetration, sub-acute care focus |
- Price inflation is constrained by payer negotiations, hospital procurement discounts, and formulary inclusion.
Regulatory and Reimbursement Factors
- Reimbursement is primarily through Medicare and private insurers, with specific billing codes (e.g., HCPCS codes).
- Reimbursement rates often influence pharmacy and hospital acquisition costs.
- Price controls and policy shifts could impact profitability margins.
Future Price Projections
- Expect gradual price stabilization with potential minor increases aligned with inflation adjustments.
- Price growth estimates for 2023-2030:
| Year |
Projected Price Increase |
Rationale |
| 2023 |
~1.5% |
Cost inflation, stable demand |
| 2025 |
~2% |
Potential supply chain disruptions, regulatory changes |
| 2030 |
~2-3% |
Market maturation, minor innovation drives, inflation adjustments |
Market Penetration Potential
- Growth hinges on expanding into emerging markets with developing healthcare infrastructure.
- Hospitals shifting procurement to cost-effective options could reduce average prices.
- Clinical adoption influenced by evidence of improved patient outcomes and formulary preferences.
Key Drivers and Risks
- Volume growth driven by increasing use in critical care.
- Price pressure from hospital procurement strategies.
- Supply chain disruptions may inflate costs.
- Regulatory environment and reimbursement policies could alter margins.
Key Takeaways
- The market for NDC 70000-0455 is mature, with steady growth driven by healthcare demand.
- Pricing is tightly regulated by payer negotiations and industry competition, with average wholesale prices around $15 per 100 mL.
- Future price increases will likely stay within 2-3% annually, constrained by broader healthcare cost containment efforts.
- Market share favors established players, with Fresenius Kabi holding approximately 40%.
FAQs
-
What are the main factors influencing the price of NDC 70000-0455?
Reimbursement rates, competitive dynamics, manufacturing costs, supply chain stability, and hospital procurement practices.
-
Can any new competitors enter the market and disrupt pricing?
Yes, but barriers include regulatory approval, formulation complexity, and established contractual relationships.
-
How does the drug's formulation impact its market position?
Advanced or customized formulations may command higher prices but face longer approval timelines and higher manufacturing costs.
-
What are the growth prospects in emerging markets?
Limited in the short term due to cost constraints, but long-term growth possible with healthcare infrastructure expansion.
-
How will pricing trends affect hospital budgets?
Moderate increases aligned with inflation, with hospitals seeking discounted procurement and alternative options to control costs.
References
[1] Grand View Research, "Parenteral Nutrition Market Size, Share & Trends," 2023.
[2] IQVIA, "Hospital and Retail Pharmacy Pricing Data," 2022.
[3] CMS HCPCS Release & Codes, 2023.
